Chasing Mylan, Hikma tries again with rejected generic Advair in US
Hikma buys potential Epipen rival from troubled Insys
Hikma rises on cancer generic deal with China’s Hansoh
Ex-Teva exec to be new Hikma CEO
Hikma to give up date in Q1 next year.
Hikma in dispute with FDA over Advair generic
FDA rejects Hikma drug, regulator has “major” issue with Mylan’s rival.
GSK gets short term boost as second US Advair generic rejected
Firms extend existing respiratory deal.
Vectura and Hikma to develop US asthma generic